# US 2022/0033794 A1 · Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033794 A1
- Document ID: US20220033794A1
- Status: Published application
- Kind: A1
- Application number: 17/391,680
- Filed: 2021-08-02
- Published: 2022-02-03
- Earliest claimed: 2017-01-24
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Daniel Batlle; Jan Wysocki
- Web page: https://patentgrep.com/patent/US20220033794A1

## CPC

- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- A61K 38/4813: {Exopeptidases (3.4.11. to 3.4.19)}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- C07K 14/765: Serum albumin, e.g. HSA
- C12Y 304/17023: Angiotensin-converting enzyme 2 (3.4.17.23)
- C07K 2319/02: containing a signal sequence
- C07K 2319/21: containing a His-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/70: containing domain for protein-protein interaction
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII(1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

A method of delivering ACE2 activity to the kidney, the method comprising administering to a subject suffering from or at risk of developing kidney damage a pharmaceutical composition that delivers into the kidney an enzymatically active ACE2 variant that is sufficiently C-terminally truncated that it is susceptible to glomerular filtration.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject is suffering from or at risk of kidney disease.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject does not demonstrate symptoms of marked alterations in glomerular permeability.

### Claim 23 (depends on 20)

The method of claim 20, wherein the subject is suffering from acute kidney injury.

### Claim 24 (depends on 20)

The method of claim 20, wherein the subject is in early phase of diabetic kidney disease.

### Claim 25 (depends on 20)

The method of claim 20, wherein the variant is a truncated human ACE2.

### Claim 26 (depends on 20)

The method of claim 20, wherein the variant is truncated at a site C-terminal to its residue analogous to residue 522 of SEQ ID NO 2.

### Claim 27 (depends on 26)

The method of claim 26, wherein the variant is N-terminally truncated.

### Claim 28 (depends on 26)

The method of claim 26, wherein the variant is characterized by elevated ACE2 activity.

### Claim 29 (depends on 26)

The method of claim 26, wherein the variant lacks a leader sequence.

### Claim 30

An active human angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to SEQ ID NO:1 at its residue analogous to residue 619 in mouse ACE2 of SEQ ID NO:2.

### Claim 31 (depends on 30)

The polypeptide of claim 30, wherein the ACE2 variant lacks a leader sequence.

### Claim 32 (depends on 30)

The polypeptide of claim 30, wherein the ACE2 variant is a fragment of SEQ ID NO:1.

### Claim 33

A fusion protein comprising:
an angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to a reference mouse homolog (SEQ ID NO:2) at a site after its residue corresponding to residue 522 of SEQ ID NO:2, so that the ACE2 variant shows ACE2 enzymatic activity, the ACE2 variant being sufficiently truncated that it is amenable to glomerular filtration and showing ACE2 enzymatic activity; and
a heterologous amino acid sequence.

### Claim 34 (depends on 33)

The fusion protein of claim 33, wherein the heterologous amino acid sequence comprises an amino acid sequence selected from the group consisting of:
(i) an amino acid sequence of the Fc portion of an antibody or a fragment thereof, which is devoid of its hinge region to prevent dimerization of the fusion polypeptide;
(ii) an amino acid sequence of domain III of human serum albumin or a fragment thereof; and
(iii) an amino acid sequence of the C-terminal albumin binding domain 3 (ABD3) of streptococcal protein G.

### Claim 35 (depends on 33)

The fusion protein of claim 33, further comprising a linker amino acid sequence between the ACE2 variant and the heterologous amino acid sequence.

### Claim 36

A conjugate comprising an angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to a reference mouse homolog (SEQ ID NO:2) at a site after its residue corresponding to residue 522 of SEQ ID NO:2, so that the ACE2 variant shows ACE2 enzymatic activity, the ACE2 variant being sufficiently truncated that it is amenable to glomerular filtration and showing ACE2 enzymatic activity conjugated to a polyethylene glycol polymer.

### Claim 37

A conjugate comprising an angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to a reference mouse homolog (SEQ ID NO:2) at a site after its residue corresponding to residue 522 of SEQ ID NO:2, so that the ACE2 variant shows ACE2 enzymatic activity, the ACE2 variant being sufficiently truncated that it is amenable to glomerular filtration and showing ACE2 enzymatic activity conjugated to a nanoparticle.

### Claim 38

A pharmaceutical composition that comprises or delivers:
an angiotensin converting enzyme 2 (ACE2) variant that is C-terminally truncated relative to a reference mouse homolog (SEQ ID NO:2) at a site after its residue corresponding to residue 619 of SEQ ID NO:2, so that the ACE2 variant shows ACE2 enzymatic activity, the ACE2 variant being sufficiently truncated that it is amenable to glomerular filtration and showing ACE2 enzymatic activity; and
a pharmaceutically acceptable carrier.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, wherein the variant lacks a leader sequence.

### Claim 40 (depends on 38)

The pharmaceutical composition of claim 38, wherein the variant has an amino acid sequence that is a fragment of SEQ ID NO:1.

### Claim 41 (depends on 21)

The method of claim 21, wherein the kidney disease is early stage kidney disease.

### Claim 42 (depends on 21)

The method of claim 21, wherein the kidney disease is chronic kidney disease.

### Claim 43 (depends on 20)

The method of claim 20, wherein the subject is at suffering from or at risk of developing scleroderma or its skin, pulmonary, kidney or hypertensive complications.

### Claim 44 (depends on 20)

The method of claim 20, wherein the subject is suffering from or at risk of diabetic or non-diabetic chronic kidney disease, acute renal failure, chronic kidney disease, severe hypertension, scleroderma or its skin, pulmonary, kidney or hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, or acute stroke.

### Claim 45 (depends on 33)

The fusion protein of claim 33, wherein the heterologous amino acid sequence is or comprises serum albumin or a fragment thereof.

### Claim 46 (depends on 33)

The fusion protein of claim 33, wherein the heterologous amino acid sequence is or comprises streptococcal protein G or a fragment thereof.
